Past Meeting Reports and Presentations

Telemedicine Listening Sessions

On September 12 and 13, 2023, DEA hosted public listening sessions and received comments from 58 healthcare practitioners, experts, advocates, patients, and other members of the public to inform DEA’s regulations on prescribing controlled substances via telemedicine.

The listening sessions were livestreamed with virtual participation available. A transcript of the listening sessions is forthcoming. All comments and presentations will become part of the official record for the purposes of rulemaking.

Access Telemedicine Listening Sessions Here!

DEA Supply Chain Conference

May 2-4, 2023

The Westin Galleria Houston

The Drug Enforcement Administration (DEA), Diversion Control Division, hosted a Supply Chain Conference May 2-4, 2023, at the Westin Galleria Houston in Houston, Texas. This conference offered those registered with the DEA as Manufacturers, Distributors, Pharmacies, Importers or Exporters the opportunity to meet, share information and discuss concerns.

This was a three-day conference. Day 1 was for manufacturers and other registrants who need quota, and for all importers and exporters. Days 2 and 3 of the conference were geared toward regulatory compliance personnel for mid-level and senior managers.

Conference Report

Tuesday, May 2, 2023 (Day 1)
Quotas and Import/Export

International Drug Treaties and the CSA
Stacy Harper-Avilla, Section Chief, Quota and UN Reporting Section

The 303 Process
Brenda Thomas, Program Analyst, Regulatory Section

Quotas – Aggregate Production Quotas, Individual Quotas, and Quota Applications
Mark Cunningham, Drug Science Specialist, Quota and UN Reporting Section

Quotas – Year End Reporting
Gregory Kavanagh, Drug Science Specialist, Quota and UN Reporting Section

Research vs Manufacturing
Minh Dang, Drug Science Specialist, Quota and UN Reporting Section

Imports and Exports of Controlled Substances and Listed Chemicals
Jacob Prieto, Acting Section Chief, Import/Export Section

Permit Applications/Declarations Process
Thomas Fahmy, Program Analyst, Import/Export Section

Re-Exports of Controlled Substances
Mark Via, Technical Information Specialist, Import/Export Section

Wednesday, May 3, 2023 (Day 2)

Holly Farrington, Program Analyst, Registration Section

Current Regulatory Priorities
Heather Achbach, Staff Coordinator, Regulatory, Drafting and Policy Support Section

ARCOS Reporting
Sam Weisman, ARCOS Team Leader, Registration Section

Stephanie Kolb, Staff Coordinator, Chemical Investigations Section

Employment Waivers/Theft and Loss Reporting
Rostant Farfan, Staff Coordinator, Regulatory Section

Administrative Actions
Kerry Hamilton, Section Chief, Pharmaceutical Investigations

Thursday, May 4, 2023 (Day 3)

IT Transformation
Matthew Strait, Deputy Assistant Administrator, Diversion Regulatory

Emerging Trends
Terrance Boos, Section Chief, Drug and Chemical Evaluation Section

Tableting & Encapsulating Machines LEADS Reporting
Stevie Ikner, Staff Coordinator, Import/Export Section

Stimulants, Quotas, and Shortages – DEA and FDA
Matthew Strait, Deputy Assistant Administrator, Diversion Regulatory
Paras Patel, Manager, Global Pharmacovigilance and Risk Management
Food and Drug Administration

Researcher Training Conference

February 6, 2019; Hilton Anaheim – Anaheim, California

The Drug Enforcement Administration (DEA) held a training conference for all DEA registered Researchers in the State of California on Wednesday, February 6, 2019. There were two sessions conducted. The content of both sessions were exactly the same.

The diversion of pharmaceutical controlled substances throughout the United States is a growing problem. This diversion stems from various sources. This training assisted these registrants in identifying and preventing diversion activity by having a greater knowledge of Federal laws and regulations that affect these registrants. The DEA provided information regarding diversion, registration (including special requirements for schedule I researchers), campus registrations, security, required records and inventories, purchasing controlled substances (including compounded controlled substances), and disposal requirements.

Over 77 Researchers attended the training. Presentations included; Registration of Schedule I-V Researchers; Procedures for Campus Registration, Compounding Drug Issues and Destruction; and Records, Reports, Inventories, and Security.

Presentations from the Researcher Training Conference are below:

Registration of Schedule I-V Researchers – Loren T. Miller, Policy Section Chief, Diversion Control Division

Procedures for Campus Registration, Compounding Drug Issues and Destruction – Lynnette Wingert, Policy Unit Chief, Diversion Control Division

Records, Reports, Inventories, and Security – Charlotte D. Barron, Regulatory Section Chief, Diversion Control Division

NOTE: Presentations by private instructors do not constitute an endorsement by the DEA of the presenters or their products or services.